Table D12. Medication adherence outcomes 4

| Author, YearTrial Name | Medication Adherence Outcome 4 | Description of Timing of Measurement of Adherence Outcome 4 | Data Source  | N | Results |
| --- | --- | --- | --- | --- | --- |
| Capoccia et al., 20049NA | Adherenceto antidepressants - at 12 mo  | Defined as use ofantidepressants for at least 25 of thepast 30 days; measured at 3, 6, 9, 12 mos | Self-report | G1: 37G2: 30 | G1: 59%G2: 57%95% CI, NRp: NS |
| Choudhry et al., 201113MI FREEE | Full adherence (among patients who filled at least 1 prescription) | Having a supply of medications available on at least 80% of days during follow-up.  | Prescription claims data | **All 3 medication classes**G1: 1385G2: 1389**ACE inhibitor** or ARBG1: 1759G2: 1775**Beta-blockers**G1: 2159G2: 2224**Statins**G1: 2223G2: 2267 | **All 3 medication classes**G1: 24.8G2: 19.3OR (95% CI): 1.36 (1.12 to 1.65)p: 0.002**ACE inhibitor or ARB**G1: 44.9G2: 38.8OR (95% CI): 1.28 (1.10 to 1.49)p: 0.002**Beta-blocker**G1: 40.4G2: 34.1OR (95% CI): 1.31 (1.14 to 1.50)p: <0.001**Statin**G1: 49.3G2: 41.9OR (95% CI): 1.36 (1.18 to 1.56)p: <0.001 |
| Hoffman et al., 200318NA | Percent adherence using medication possession ratios, at 6 months | Measured once at 6 months for previous 30 days; adherence defined as < 10 days in 30-day period  | PRD | G1: 4899G2: 4665 | G1: 52.3G2: 50.295% CI, NRp: <0.001 |
| Katon et al., 199625NA | Adequate dosage | A dosage of antidepressant medication for at least 30 days at or above lowest dosage recommended by AHCPR guidelines | PRD | G1: 76G2: NS | **Major Depression Group, for at least 30 days** (% adherent)G1: 66.7%G2: 57.6%p<.46**Minor Depression Group, for at least 30 days** (% adherent)G1: 84.8%G2: 53.9%to <0.002 |
| Montori et al., 201135NA | Adherence: did not miss a dose | Asked at 6 months: "Have you missed any of your pills in the past week?" | Self-report | G1: 17G2: 19 | G1: 65%G2: 63%95% CI, NRp: 0.92 |
| Murray et al., 200736NA | "Scheduling Adherence": Measure of adherence to timing, lower with day-to-day deviation in the timing of medication administration; daily meds need to be taken within 2.4 hrs of dose from preceding day; 2x/day meds need to be taken within 1.2 hrs of prior dose | Post-intervention (3 additional mos - months 10-12)Frequency: continuous daily MEMS monitoringDuration between measures: 12 to 24 hours, depending on med frequency | MEMS | G1: 122G2: 192 |  (95% CI)G1: 48.9% (43.7 to 54.1)G2: 48.6% (44.7 to 52.6)Difference: 0.3 (-5.9 to 6.5)p: NR  |
| Nietert et al., 200937NA | Filled prescription for any medication, within 30 days of index date | NR | PRD | G1: 1018G2: 1016G3: 1014 | UnadjustedG1: N (%) = 460 (45.2%)G2: N (%) = 484 (47.6%)G3: N (%) = 490 (48.3%)95% CI, NRp: NRAdjustedG1: Hazard ratio (HR, 98.3% CI) = 0.86 (0.68 to 1.08)G2: HR, 95.0% CI = 0.99 (0.81 to 1.19)G3: HR, 97.5% CI = 0.87 (0.70 to 1.08)95% CI, NRp: NR |
| Pyne et al., 201141HIV Translating Initiatives for Depression Into Effective Solutions (HITIDES) | HIV medication regiment adherence - at 12 months | Each measurement is percentage adherence over previous 4 days (i.e. total number of prescribed pills taken divided by total number of prescribed, transformed to dichotomous outcome with cutpoint at >=95%). 3 measurements taken: baseline, 6-month and 12-months.  | Self-report | G1: 68/92 (73.9)G2: 64/86 (74.4) | G1: 68/92 (73.9)G2: 64/86 (74.4)OR: 0.93 (0.46 to 1.90), adjusted OR: 1.60 (0.50 to 2.33)Adjusted p: 0.89 |
| Rich et al., 199642NA | >80% compliance by method 2 | 30 days +/- 2 days after discharge; 1 time; NA | Pill count | G1: 80G2: 76 | Overall: 74.7%G1: 82.5%G2: 66.2%95% CI, NRp: 0.033 |
| Stacy et al., 200956NA | Continuous persistence +Medication possession ratio =/>80% | 6 months from baseline; 1 time; NA | PRD | G1: 253G2: 244 | G1: 45.1%G2: 37.3%Unadjusted OR (90% CI): 1.38 (1.03 to 1.86)Adjusted OR (90%CI): 1.41 (1.03 to 1.92)p: <0.10 |
| Vivian et al.,200258 NA | Compliance survey at 6 months: When your medication does not seem to be working, how often do you take more than your health care provider prescribed? (>=once/wk) | Varied b/t groups; compliance measured in G1 at monthly visits, only measured at baseline and study end for G2 | Self-report | G1: 26G2: 27 | G1: 8%G2: 8%95% CI, NRp: 1.00 |
| Wilson et al., 201065Better Outcomes of Asthma Treatment (BOAT) | Controller regimen anti-inﬂammatory potency - mean equivalents of acquisition of beclome-thasone canister equivalents - year 1 | Measured as aggregate for entire year | PRD | G1: 204G2: 202G3: 204 | G1: 10.9G3: 5.2;Group difference: 5.895% CI, 4.5 to 7.0p< 0.0001G1: 10.9G2: 9.1;Group difference: 1.895% CI, 0.57 to 3.1p: 0.005G2: 9.1G3: 5.2Group difference: 3.995% CI, 2.6 to 5.2p: <0.0001 |